{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:22:48Z","timestamp":1772166168074,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Assessment of health-related quality of life (HRQoL) are often measured as an important patient-reported outcome (PRO) in clinical studies. Pulmonary arterial hypertension (PAH) is a common complication of atrial septal defect (ASD). This study aimed to compare the HRQoL of PAH related uncorrected secundum ASD at pre and post therapy with oral sildenafil therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted quasi experimental study at Sardjito General Hospital Yogyakarta since April 2016 to August 2017. Adults with PAH related uncorrected secundum ASD, listed on Congenital Heart Disease and Pulmonary Hypertension (COHARD-PH) registry, and met the inclusion and exclusion criteria were recruited as subject. Interview was done at pre and 12\u2009weeks post oral sildenafil therapy 3\u2009\u00d7\u200920\u2009mg using the EQ-5D-3L questionnaire. Statistical analysis was done using Wilcoxon test and paired T-test to determine the differences of EQ-5D utility and EQ-VAS score at pre and post therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 18 adult patients with PAH related to uncorrected secundum ASD were enrolled in this study (83.33% female; mean age 38.72\u2009\u00b1\u200910.81\u2009years old). The most frequent reported problems pre therapy were pain\/discomfort (83%) and anxiety\/depression (78%). Wilcoxon test showed the median of EQ-5D utility score were increased after sildenafil therapy (before\u2009=\u20090.604, after\u2009=\u20090.664; Z\u2009=\u2009\u2212\u20092703; p:0.007), respectively. Meanwhile, the paired T-test results showed an increase of EQ-VAS mean difference 6.67\u2009\u00b1\u20098.75 (p:0.005; 95% CI 2.32\u201311.02) after sildenafil therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The administration of oral sildenafil therapy 3\u2009\u00d7\u200920\u2009mg during 12\u2009weeks in adult patients with PAH related uncorrected secundum ASD gives better HRQoL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12955-020-01498-7","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T09:03:00Z","timestamp":1597395780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The effect of oral sildenafil therapy on health-related quality of life in adults with pulmonary arterial hypertension related to uncorrected secundum atrial septal defect: a quasi experimental study"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4349-4640","authenticated-orcid":false,"given":"Fera","family":"Hidayati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Putrika P. R.","family":"Gharini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anggoro Budi","family":"Hartopo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dyah Wulan","family":"Anggrahini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia Kris","family":"Dinarti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,14]]},"reference":[{"issue":"126","key":"1498_CR1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1183\/09059180.00004712","volume":"21","author":"M D\u2019Alto","year":"2012","unstructured":"D\u2019Alto M, Mahadevan VS. Pulmonary arterial hypertension associated with congenital heart disease. Eur Respir Rev. 2012;21(126):328\u201337.","journal-title":"Eur Respir Rev"},{"key":"1498_CR2","volume-title":"Disertasi. Program Doktor Ilmu Kedokteran dan Kesehatan FK UGM","author":"LK Dinarti","year":"2017","unstructured":"Dinarti LK. Hubungan antara kadar prostasiklin, nitrogen monoksida, endotelin-1 dengan hipertensi arteri pulmonal pada pasien defek septum atrium dewasa yang belum dikoreksi. In: Disertasi. Program Doktor Ilmu Kedokteran dan Kesehatan FK UGM; 2017."},{"key":"1498_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12471-013-0432-9","volume":"21","author":"MC Post","year":"2013","unstructured":"Post MC. Association between pulmonary hypertension and an atrial septal defect. Neth Hear J. 2013;21:331\u20132.","journal-title":"Neth Hear J"},{"key":"1498_CR4","volume-title":"Systematic review of health-related quality of life in patients with pulmonary arterial hypertension. PharmacoEconomics","author":"S Gu","year":"2016","unstructured":"Gu S, Hu H, Dong H. Systematic review of health-related quality of life in patients with pulmonary arterial hypertension. PharmacoEconomics. Switzerland: Springer International Publishing; 2016."},{"issue":"4","key":"1498_CR5","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1590\/S0066-782X2012005000079","volume":"99","author":"C C\u00edcero","year":"2012","unstructured":"C\u00edcero C, Franchi SM, Barreto AC, Lopes AAB. Lack of tight association between quality of life and exercise capacity in pulmonary arterial hypertension. Arq Bras Cardiol. 2012;99(4):876\u201385.","journal-title":"Arq Bras Cardiol"},{"key":"1498_CR6","first-page":"1","volume":"13","author":"SC Mathai","year":"2015","unstructured":"Mathai SC, Suber T, Khair RM, Kolb TM, Damico RL, Hassoun PM. Health-related quality of life and survival in pulmonary arterial hypertension. Ann Am Thorac Soc. 2015;13:1\u201331.","journal-title":"Ann Am Thorac Soc"},{"key":"1498_CR7","first-page":"531e537","volume":"108","author":"R Wang","year":"2014","unstructured":"Wang R, Jiang F, Zheng Q, Li C, Peng X, He C, et al. Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension. Respir Med. 2014;108:531e537.","journal-title":"Respir Med"},{"key":"1498_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1378\/chest.07-0592","volume":"133","author":"J Pepke-Zaba","year":"2008","unstructured":"Pepke-Zaba J, Gilbert C, Collings L, MCJ B. Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension. CHEST. 2008;133:183\u20139.","journal-title":"CHEST"},{"issue":"4","key":"1498_CR9","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","volume":"169","author":"RJ Barst","year":"2004","unstructured":"Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;169(4):441\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"1498_CR10","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1136\/ard.2007.069609","volume":"66","author":"RE Girgis","year":"2007","unstructured":"Girgis RE, Frost AE, Hill NS, Horn EM, Langleben D, McLaughlin VV, et al. Selective endothelin a receptor antagonism with Sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis. 2007;66(11):1467\u201372.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1498_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.healun.2006.11.009","volume":"26","author":"AM Keogh","year":"2007","unstructured":"Keogh AM, McNeil KD, Wlodarczyk J, Gabbay E, Williams TJ. Quality of life in pulmonary arterial hypertension: improvement and maintenance with Bosentan. J Heart Lung Transplant. 2007;26(2):181\u20137.","journal-title":"J Heart Lung Transplant"},{"key":"1498_CR12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/1477-7525-11-161","volume":"11","author":"N Bonner","year":"2013","unstructured":"Bonner N, Abetz L, Meunier J, Sikirica M, Mathai SC. Development and validation of the living with pulmonary hypertension questionnaire in pulmonary hypertension patients. Health Qual Life Outcomes. 2013;11:161.","journal-title":"Health Qual Life Outcomes"},{"key":"1498_CR13","first-page":"1","volume":"1","author":"MV Reenen","year":"2015","unstructured":"Reenen MV, Oppe M. EQ-5D-3L user guide basic information on how to use the EQ-5D-3L instrument. EuroQol Res Found. 2015;1:1\u201320.","journal-title":"EuroQol Res Found"},{"issue":"2","key":"1498_CR14","first-page":"131","volume":"5","author":"A Sari","year":"2015","unstructured":"Sari A, Lestari ND, Perwitasari DA. Validasi St European Quality of Life-5 Dimensions (EQ-5D) Versi Indonesia pada Pasien Hipertensi di Puskesmas Kotagede II Yogyakarta. Pharmaciana. 2015;5(2):131\u20138.","journal-title":"Pharmaciana"},{"key":"1498_CR15","first-page":"1","volume":"1","author":"C Phillips","year":"2001","unstructured":"Phillips C, Thompson G. What is a QALY? Hayward Medl Commun. 2001;1:1\u20135.","journal-title":"Hayward Medl Commun"},{"issue":"1","key":"1498_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jval.2011.11.024","volume":"15","author":"FA Yusof","year":"2012","unstructured":"Yusof FA, Goh A, Azmi S. Estimating an EQ-5D value set for Malaysia using TTO and VAS methods. Value Health. 2012;15(1):85\u201390.","journal-title":"Value Health"},{"key":"1498_CR17","doi-asserted-by":"publisher","first-page":"A807","DOI":"10.1016\/j.jval.2016.08.460","volume":"19","author":"D Endarti","year":"2016","unstructured":"Endarti D, Riewpaiboon A, Thavorncharoensap M, Praditsitthikorn N, Hutubessy R, Kristina SA. A comparison of EQ-5D-3L index scores using foreign value sets for Indonesian sample with cervical cancer. Value Health. 2016;19:A807\u2013918.","journal-title":"Value Health"},{"issue":"1","key":"1498_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3329\/bhj.v30i1.28133","volume":"30","author":"S Haque","year":"2016","unstructured":"Haque S, Khan LR, Mahmud RS. Faruq, Chowdury a.W., Ali M.S. pulmonary artery pressure profile in atrial septal defect patients. Bangladesh Heart J. 2016;30(1):27\u20138.","journal-title":"Bangladesh Heart J"},{"key":"1498_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/hrt.82.1.30","volume":"82","author":"M Vogel","year":"1999","unstructured":"Vogel M, Berger F, Kramer A, Alexi-Meshkishvili V, Lange PE. Incidence of secondary pulmonary hypertension in adults with atrial septal or sinus venosus defects. Heart. 1999;82:30\u20133.","journal-title":"Heart."},{"key":"1498_CR20","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1136\/hrt.2006.098848","volume":"93","author":"PM Engelfriet","year":"2007","unstructured":"Engelfriet PM, Duffels MGJ, Moller T, Boersma E, Tijssen JGP, Thaulow E, et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the euro heart survey on adult congenital heart disease. Heart. 2007;93:682\u20137.","journal-title":"Heart"},{"key":"1498_CR21","first-page":"239","volume-title":"17th Plenary Meeting of the EuroQoL Group, Pampiona, 28\u201329 September 2000. Discussion paper","author":"S Thompson","year":"2001","unstructured":"Thompson S, Fichte K, Miltenburger C, Nikkho S, Higenbottam T, Olschewski H, Seeger W. Measuring health-related quality of life with the EuroQoL EQ-5D instrument in clinical trials of new treatments for pulmonary hypertension. In: 17th Plenary Meeting of the EuroQoL Group, Pampiona, 28\u201329 September 2000. Discussion paper. Spain: Universad Publica de Navarra; 2001. p. 239\u201348."},{"key":"1498_CR22","doi-asserted-by":"crossref","unstructured":"Mychaskiw M.A., Berger A., Mardekian J., Hwang L.J., Oster G. Methods for Estimating Health-State Utilities in Pulmonary Arterial Hypertension. Value Health. 2010;13(7):A239\u2013501.","DOI":"10.1016\/S1098-3015(11)72450-0"},{"key":"1498_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jacc.2003.10.056","volume":"43","author":"BKS Sastry","year":"2004","unstructured":"Sastry BKS, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension. J Am Coll Cardiol. 2004;43:7.","journal-title":"J Am Coll Cardiol"},{"key":"1498_CR24","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ijcard.2006.07.170","volume":"119","author":"RCC Wong","year":"2007","unstructured":"Wong RCC, Koh GM, Choong PH, Yip WLJ. Oral sildenafil therapy improves health-related quality of life and functional status in pulmonary arterial hypertension. Int J Cardiol. 2007;119:400\u20132.","journal-title":"Int J Cardiol"},{"key":"1498_CR25","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ijcard.2010.02.020","volume":"149","author":"ELW Tay","year":"2011","unstructured":"Tay ELW, Papaphylactou M, Diller GP, Alonso-Gonzalez R, Inuzuka R, Giannakoulas G, et al. Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy. Int J Cardiol. 2011;149:372\u20136.","journal-title":"Int J Cardiol"},{"issue":"2","key":"1498_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1586\/14737167.2014.894462","volume":"14","author":"S Coretti","year":"2014","unstructured":"Coretti S, Ruggeri M, Mcnamee P. The minimum clinically important difference for EQ-5D index: a critical review. Expert Rev Pharmacoecon Outcomes Res. 2014;14(2):221\u201333. https:\/\/doi.org\/10.1586\/14737167.2014.894462.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"1498_CR27","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1177\/1049909114554079","volume":"33","author":"LA Matura","year":"2014","unstructured":"Matura LA, McDonough A, Carroll DL. Symptom prevalence, symptom severity, and health-related quality of life among young, middle, and older adults with pulmonary arterial hypertension. Am J Hosp Palliat Care. 2014;33(3):214 http:\/\/ajh.sagepub.com\/content\/early\/2014\/10\/01\/1049909114554079.","journal-title":"Am J Hosp Palliat Care"},{"issue":"1","key":"1498_CR28","first-page":"5","volume":"2","author":"A Tyrka","year":"2014","unstructured":"Tyrka A, Sarnecka A, Jonas K, Waligora M, Kopec G, Podolec P. Health-related quality of life in pulmonary arterial hypertension (RCD code: II). J Rare Cardiovasc Dis. 2014;2(1):5\u20138.","journal-title":"J Rare Cardiovasc Dis"},{"key":"1498_CR29","volume-title":"Aspects of health-related quality of life. Associations with psychosocial and biological factors, and use as patient-reported outcome in routine health care","author":"E Nilsson","year":"2012","unstructured":"Nilsson E. Aspects of health-related quality of life. Associations with psychosocial and biological factors, and use as patient-reported outcome in routine health care. Sweden: Link\u00f6ping University Medical Dissertations No. 1295; 2012."},{"key":"1498_CR30","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1183\/16000617.0063-2015","volume":"24","author":"M Delcroix","year":"2015","unstructured":"Delcroix M, Howard L. Pulmonary arterial hypertension: the burden of disease and impact on quality of life. Eur Respir Rev. 2015;24:621\u20139.","journal-title":"Eur Respir Rev"},{"key":"1498_CR31","first-page":"5","volume":"1","author":"N Gali\u00e8","year":"2015","unstructured":"Gali\u00e8 N, Hoeper MM, Humbert M, Vachiery JL, Gibbs S, Lang I, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2015;1:5\u201347.","journal-title":"Eur Heart J"},{"issue":"40","key":"1498_CR32","first-page":"1","volume":"6","author":"AC van Dissel","year":"2017","unstructured":"van Dissel AC, Mulder BJ, Bouma BJ. The changing landscape of pulmonary arterial hypertension in the adult with congenital heart disease. J Clin Med. 2017;6(40):1\u201322.","journal-title":"J Clin Med"},{"key":"1498_CR33","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.rmed.2008.04.016","volume":"102","author":"M Zlupko","year":"2008","unstructured":"Zlupko M, Harhay MO, Gallop R, Shin J, Archer-Chicko C, Patel R, et al. Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension. Respir Med. 2008;102:1431\u20138.","journal-title":"Respir Med"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-020-01498-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12955-020-01498-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-020-01498-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T18:18:46Z","timestamp":1667758726000},"score":1,"resource":{"primary":{"URL":"https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/s12955-020-01498-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,14]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1498"],"URL":"https:\/\/doi.org\/10.1186\/s12955-020-01498-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.22167\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.22167\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.22167\/v3","asserted-by":"object"}]},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,14]]},"assertion":[{"value":"23 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Patients provided written informed consent to participate in the study. This study was ethically approved by the ethical commission of biomedical research Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta and permission from the Director of Dr. Sardjito General Hospital Yogyakarta. Patients provided written informed consent to participate in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"278"}}